65 drugs reach their earliest generic-entry date in 2032

Jan 2032 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Grafapex · 2 strengths treosulfan	treosulfan	Medexus	214759	21 Jan 2032	exclusivity

Feb 2032 · 5

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Moxidectin moxidectin	moxidectin	Mdgh	210867	7 Feb 2032	exclusivity
Cometriq · 2 strengths cabozantinib s-malate	cabozantinib s-malate	Exelixis	203756	10 Feb 2032	patent
Kybella deoxycholic acid	deoxycholic acid	Abbvie	206333	17 Feb 2032	patent, carve-out possible
Joenja leniolisib phosphate	leniolisib phosphate	Pharming	217759	19 Feb 2032	patent
Ctexli chenodiol	chenodiol	Mirum	219488	21 Feb 2032	exclusivity

Mar 2032 · 7

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Neupro · 6 strengths rotigotine	rotigotine	Ucb Inc	021829	1 Mar 2032	patent
Neoprofen ibuprofen lysine	ibuprofen lysine	Recordati Rare	021903	2 Mar 2032	patent
Dexilant · 2 strengths dexlansoprazole	dexlansoprazole	Takeda Pharms Usa	022287	5 Mar 2032	patent, carve-out possible
Caldolor · 2 strengths ibuprofen	ibuprofen	Apotex	022348	16 Mar 2032	patent, carve-out possible
Jornay Pm · 5 strengths methylphenidate hydrochloride	methylphenidate hydrochloride	Ironshore Pharms	209311	23 Mar 2032	patent
Isentress Hd raltegravir potassium	raltegravir potassium	Msd Sub Merck	022145	30 Mar 2032	patent, carve-out possible
Ilevro nepafenac	nepafenac	Harrow Eye	203491	31 Mar 2032	patent

Apr 2032 · 5

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Movantik · 2 strengths naloxegol oxalate	naloxegol oxalate	Averitas	204760	2 Apr 2032	patent
Acetadote acetylcysteine	acetylcysteine	Apotex	021539	6 Apr 2032	patent, carve-out possible
Rykindo risperidone	risperidone	Shandong Luye	212849	10 Apr 2032	patent
Firmagon · 2 strengths degarelix acetate	degarelix acetate	Ferring	022201	27 Apr 2032	patent, carve-out possible
Cycloset bromocriptine mesylate	bromocriptine mesylate	Veroscience	020866	30 Apr 2032	patent

May 2032 · 8

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Voquezna · 2 strengths vonoprazan fumarate	vonoprazan fumarate	Phathom	215151	3 May 2032	exclusivity
Voquezna Dual Pak amoxicillin; vonoprazan fumarate	amoxicillin; vonoprazan fumarate	Phathom	215153	3 May 2032	exclusivity
Voquezna Triple Pak amoxicillin; clarithromycin; vonoprazan fumarate	amoxicillin; clarithromycin; vonoprazan fumarate	Phathom	215152	3 May 2032	exclusivity
Rivive naloxone hydrochloride	naloxone hydrochloride	Harm Reduction Therp	217722	11 May 2032	patent
Varithena polidocanol	polidocanol	Boston Scitfc	205098	12 May 2032	patent
Pataday Once Daily Relief olopatadine hydrochloride	olopatadine hydrochloride	Alcon Labs Inc	206276	19 May 2032	patent
Fetzima · 4 strengths levomilnacipran hydrochloride	levomilnacipran hydrochloride	Abbvie	204168	23 May 2032	patent
Tauvid · 2 strengths flortaucipir f-18	flortaucipir f-18	Avid Radiopharms Inc	212123	26 May 2032	patent

Jun 2032 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Zelboraf vemurafenib	vemurafenib	Hoffmann La Roche	202429	6 Jun 2032	patent
Harliku nitisinone	nitisinone	Cycle	209449	10 Jun 2032	exclusivity
Avycaz avibactam sodium; ceftazidime	avibactam sodium; ceftazidime	Abbvie	206494	15 Jun 2032	patent
Defitelio defibrotide sodium	defibrotide sodium	Jazz Pharms Inc	208114	22 Jun 2032	patent
Adzenys Xr-Odt · 6 strengths amphetamine	amphetamine	Neos Theraps	204326	28 Jun 2032	patent
Nuvessa metronidazole	metronidazole	Alembic Therap	205223	28 Jun 2032	patent

Jul 2032 · 7

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Precedex · 3 strengths dexmedetomidine hydrochloride	dexmedetomidine hydrochloride	Hospira	021038	4 Jul 2032	patent
Stivarga regorafenib	regorafenib	Bayer Hlthcare	203085	9 Jul 2032	patent
Neuraceq florbetaben f-18	florbetaben f-18	Lantheus	204677	14 Jul 2032	patent
Doptelet avatrombopag maleate	avatrombopag maleate	Akarx Inc	210238	24 Jul 2032	exclusivity
Doptelet Sprinkle avatrombopag maleate	avatrombopag maleate	Akarx Inc	219696	24 Jul 2032	exclusivity
Brixadi · 7 strengths buprenorphine	buprenorphine	Braeburn	210136	26 Jul 2032	patent
Tavalisse · 2 strengths fostamatinib disodium	fostamatinib disodium	Rigel Pharms	209299	27 Jul 2032	patent

Aug 2032 · 5

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Tpoxx tecovirimat	tecovirimat	Siga Technologies	208627	8 Aug 2032	patent, carve-out possible
Netspot gallium dotatate ga-68	gallium dotatate ga-68	Novartis	208547	10 Aug 2032	patent
Aptiom · 4 strengths eslicarbazepine acetate	eslicarbazepine acetate	Sumitomo Pharma Am	022416	24 Aug 2032	patent, carve-out possible
Idvynso doravirine; islatravir	doravirine; islatravir	Msd	216964	30 Aug 2032	patent
Pifeltro doravirine	doravirine	Msd Merck Co	210806	30 Aug 2032	patent

Sep 2032 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Zubsolv · 6 strengths buprenorphine hydrochloride; naloxone hydrochloride	buprenorphine hydrochloride; naloxone hydrochloride	Edenbridge Pharms	204242	18 Sep 2032	patent
Trintellix · 3 strengths vortioxetine hydrobromide	vortioxetine hydrobromide	Takeda Pharms Usa	204447	21 Sep 2032	patent
Vazalore · 2 strengths aspirin	aspirin	Plx Pharma	203697	29 Sep 2032	patent
Gilenya fingolimod hydrochloride	fingolimod hydrochloride	Novartis	022527	30 Sep 2032	patent

Oct 2032 · 8

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Levothyroxine Sodium · 3 strengths levothyroxine sodium	levothyroxine sodium	Fresenius Kabi Usa	202231	3 Oct 2032	patent
Evotaz atazanavir sulfate; cobicistat	atazanavir sulfate; cobicistat	Bristol	206353	6 Oct 2032	patent
Prezcobix · 2 strengths cobicistat; darunavir ethanolate	cobicistat; darunavir ethanolate	Janssen Prods	205395	6 Oct 2032	patent
Tasigna · 3 strengths nilotinib hydrochloride	nilotinib hydrochloride	Novartis	022068	7 Oct 2032	patent
Minocin minocycline hydrochloride	minocycline hydrochloride	Rempex	050444	16 Oct 2032	patent
Talzenna · 6 strengths talazoparib tosylate	talazoparib tosylate	Pfizer	217439	16 Oct 2032	patent
Dehydrated Alcohol dehydrated alcohol	dehydrated alcohol	Be Pharms	214988	23 Oct 2032	exclusivity
Livmarli maralixibat chloride	maralixibat chloride	Mirum	214662	26 Oct 2032	patent, carve-out possible

Nov 2032 · 7

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Torisel temsirolimus	temsirolimus	Pf Prism Cv	022088	10 Nov 2032	patent
Korsuva difelikefalin acetate	difelikefalin acetate	Vifor Intl	214916	12 Nov 2032	patent
Koselugo · 2 strengths selumetinib sulfate	selumetinib sulfate	Astrazeneca	219943	19 Nov 2032	exclusivity
Koselugo · 2 strengths selumetinib sulfate	selumetinib sulfate	Astrazeneca	213756	19 Nov 2032	exclusivity
Bijuva · 2 strengths estradiol; progesterone	estradiol; progesterone	Mayne Pharma	210132	21 Nov 2032	patent
Verquvo · 3 strengths vericiguat	vericiguat	Msd	214377	26 Nov 2032	patent
Olumiant · 3 strengths baricitinib	baricitinib	Eli Lilly And Co	207924	30 Nov 2032	patent, carve-out possible

Dec 2032 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ongentys · 2 strengths opicapone	opicapone	Amneal	212489	12 Dec 2032	patent
Belbuca · 7 strengths buprenorphine hydrochloride	buprenorphine hydrochloride	Bdsi	207932	21 Dec 2032	patent, carve-out possible